Fc-Fusion Protein Patents: Who Leads, Where the Gaps Are 2026
Fc-fusion protein production patents: who holds the process claims and where they stop
18 families from the leading filer versus 8 at fifth place — a steep drop-off rather than an even spread across the 16 ranked assignees. Filings hit 13 in 2017, the peak across the window. By 2021 the annual count had fallen to 3, and by 2024 — the last complete year — to 1, a -67% move over that span. Read the 2025-2026 bars as incomplete rather than as a continuation of the decline.
- 1PFIZER INC18
- 2LONZA AG14
- 3THERIPION INC14
- 4TRILLIUM THERAPEUTICS INC11
- 5PF ARGENTUM IP HOLDINGS LLC8
See the full fusion protein manufacturing — fc-fusion protein production patent landscape analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on Fc-fusion protein production patents
Who holds the most Fc-fusion protein production patents?
Among the 16 assignees in this ranked dataset, one company leads with 18 patent families, well ahead of the fifth-placed filer at 8 and the tenth at 1. Co-assignee links between the leader and a related IP-holding entity account for some of that concentration, suggesting corporate restructuring or spin-out activity rather than a single unified filing strategy. Because this is the full ranking the dataset returns rather than a top-50 or top-100 cut, the drop-off from leader to long tail is a genuine feature of the field, not a sampling artifact.
Is patent filing activity in Fc-fusion protein manufacturing growing or declining?
Filings peaked at 13 in 2017 and declined to 1 by 2024, a -67% change from the 3 filed in 2021 — the last three-year span this dataset treats as complete. Publication lags filing by roughly 18 months, so the near-zero counts shown for 2025 and 2026 are undercounts still filling in, not proof of continued decline. The safest read is a plateau at a lower filing rate since the 2017 peak, not a field in active retreat.
What patent classifications cover Fc-fusion protein production?
This landscape is built around IPC classes C12P21/08 (peptide fermentation), C07K16/00 (immunoglobulins) and C12N15/62 (fusion polypeptides), combined with production and manufacturing search terms. Within the resulting 78 records, C07K appears on all of them and C12N on 96.2%, meaning the two effectively co-occur across the corpus. C12P fermentation/enzymatic-synthesis codes are comparatively rare at 19.2% of records, which is notable given that fermentation-scale process steps are central to actually manufacturing these proteins at commercial volume.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Fusion Protein Manufacturing — Fc-Fusion Protein Production Patent Landscape covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.